Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ

NCT00088738 | Completed Phase 1

• 2 other identifiers: 04018904-M-0189
• Study Type: interventional
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to observe the effects of a panic attack in patients with panic disorders and to demonstrate the involvement of Substance P in panic disorder, and thereby, further our understanding of its role in this illness. We will measure levels of Substance P in the brain by obtaining pictures of the brain using PET and MRI....

Conditions

Panic Disorder; Healthy

Keywords

Tachykinin; Anxiety; Neuroreceptor; Internalization; Carbon Dioxide; Healthy Volunteer; HV; Panic Disorder

Interventions

[18F] SPA-RQ DRUG

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy Adults ages 18-50

You may not qualify if:

• History of psychiatric disease, substance dependence or traumatic brain injury, severe systemic disease, poor vision or hearing
• History of substance abuse within 6 months
• Abnormal laboratory tests, including HIV test
• Any prior participation in other research protocols involving radiation exposure within the past year
• Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits. Limits: A total effective dose 2.5 rem in a year and 2.5 rad per year to the lens of the eyes, gonads and blood-forming organs; and 7.5 rad annually for all other organs.
• Pregnancy and Breast Feeding.
• Positive HIV test
• Ages 18-50
• Male or Female
• Informed consent given
• Subjects who regularly consume caffeinated beverages.
• DSM-IV Axis I diagnostic criteria such as history of, or current Dx ADHD, mood/anxiety disorder, alcohol or psychoactive substance abuse/dependence
• Psychotropic medication or other drugs that may cross the blood brain barrier
• Traumatic brain injury, severe systemic disease
• Abnormal MRI other than minor atrophy

Sponsors & Collaborators

• National Institute of Mental Health (NIMH): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NM. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998 Sep 11;281(5383):1640-5. doi: 10.1126/science.281.5383.1640.

  PMID: 9733503 BACKGROUND

• Stockmeier CA, Shi X, Konick L, Overholser JC, Jurjus G, Meltzer HY, Friedman L, Blier P, Rajkowska G. Neurokinin-1 receptors are decreased in major depressive disorder. Neuroreport. 2002 Jul 2;13(9):1223-7. doi: 10.1097/00001756-200207020-00031.

  PMID: 12151774 BACKGROUND

• Deguchi K, Antalffy BA, Twohill LJ, Chakraborty S, Glaze DG, Armstrong DD. Substance P immunoreactivity in Rett syndrome. Pediatr Neurol. 2000 Apr;22(4):259-66. doi: 10.1016/s0887-8994(00)00120-x.

  PMID: 10788742 BACKGROUND

MeSH Terms

Conditions

Panic Disorder; Anxiety Disorders

Interventions

(2-fluoromethoxy-5-(5-trifluoromethyltetrazol-1-yl)benzyl)(2-phenylpiperidin-3-yl)amine

Condition Hierarchy (Ancestors)

Mental Disorders

Study Design

• Study Type: interventional
• Phase: phase 1
• Purpose: TREATMENT
• Sponsor Type: NIH

Study Record Dates

• First Submitted: July 30, 2004
• First Posted: August 2, 2004
• Study Start: July 27, 2004
• Study Completion: September 10, 2008
• Last Updated: July 2, 2017

Record last verified: 2008-09-10

Locations

US (1)